• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

High incidence of MYD88 and KMT2D mutations in Chinese with chronic lymphocytic leukemia.

作者信息

Yi Shuhua, Yan Yuting, Jin Meiling, Xiong Wenjie, Yu Zhen, Yu Ying, Cui Rui, Wang Jun, Wang Yi, Lin Yani, Jia Yujiao, Zhang Donglei, Wang Tingyu, Lv Rui, Liu Wei, Sui Weiwei, Huang Wenyang, Fu Mingwei, Xu Yan, Deng Shuhui, An Gang, Zou Dehui, Li Zengjun, Shi Jun, Xiao Zhijian, Wang Jianxiang, Cheng Tao, Gale Robert Peter, Wang Lili, Qiu Lugui

机构信息

State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Blood Diseases Hospital & Institute of Hematology, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, 300020, China.

Department of Systems Biology, Beckman Research Institute, City of Hope National Comprehensive Cancer Center, Monrovia, CA, 91016, USA.

出版信息

Leukemia. 2021 Aug;35(8):2412-2415. doi: 10.1038/s41375-021-01124-5. Epub 2021 Jan 22.

DOI:10.1038/s41375-021-01124-5
PMID:33483618
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8295410/
Abstract
摘要

相似文献

1
High incidence of MYD88 and KMT2D mutations in Chinese with chronic lymphocytic leukemia.中国慢性淋巴细胞白血病患者中MYD88和KMT2D突变的高发生率。
Leukemia. 2021 Aug;35(8):2412-2415. doi: 10.1038/s41375-021-01124-5. Epub 2021 Jan 22.
2
Frequencies of SF3B1, NOTCH1, MYD88, BIRC3 and IGHV mutations and TP53 disruptions in Chinese with chronic lymphocytic leukemia: disparities with Europeans.中国慢性淋巴细胞白血病患者中SF3B1、NOTCH1、MYD88、BIRC3和IGHV突变频率及TP53基因破坏情况：与欧洲人的差异
Oncotarget. 2015 Mar 10;6(7):5426-34. doi: 10.18632/oncotarget.3101.
3
Clinical impact of MYD88 mutations in chronic lymphocytic leukemia.MYD88突变在慢性淋巴细胞白血病中的临床影响
Blood. 2016 Mar 24;127(12):1611-3. doi: 10.1182/blood-2015-10-678490. Epub 2016 Feb 4.
4
Prognostic relevance of MYD88 mutations in CLL: the jury is still out.MYD88突变在慢性淋巴细胞白血病中的预后相关性：尚无定论。
Blood. 2015 Aug 20;126(8):1043-4. doi: 10.1182/blood-2015-05-648634.
5
Lack of Associations between TLR9 and MYD88 Gene Polymorphisms and Risk of Chronic Lymphocytic Leukemia.Toll样受体9（TLR9）和髓样分化因子88（MYD88）基因多态性与慢性淋巴细胞白血病风险之间无关联。
Asian Pac J Cancer Prev. 2017 Dec 29;18(12):3245-3250. doi: 10.22034/APJCP.2017.18.12.3245.
6
Genetic characterization of MYD88-mutated lymphoplasmacytic lymphoma in comparison with MYD88-mutated chronic lymphocytic leukemia.MYD88 突变性淋巴浆细胞淋巴瘤与 MYD88 突变性慢性淋巴细胞白血病的遗传学特征比较。
Leukemia. 2017 Jun;31(6):1355-1362. doi: 10.1038/leu.2016.330. Epub 2016 Nov 14.
7
Targeted next-generation sequencing in chronic lymphocytic leukemia: a high-throughput yet tailored approach will facilitate implementation in a clinical setting.慢性淋巴细胞白血病的靶向新一代测序：一种高通量且量身定制的方法将促进其在临床环境中的应用。
Haematologica. 2015 Mar;100(3):370-6. doi: 10.3324/haematol.2014.109777. Epub 2014 Dec 5.
8
MYD88 mutations predict unfavorable prognosis in Chronic Lymphocytic Leukemia patients with mutated IGHV gene.MYD88突变预示着免疫球蛋白重链可变区（IGHV）基因发生突变的慢性淋巴细胞白血病患者预后不良。
Blood Cancer J. 2017 Dec 15;7(12):651. doi: 10.1038/s41408-017-0014-y.
9
MYD88 mutation analysis of a rare composite chronic lymphocyte leukemia and lymphoplasmacytic lymphoma by flow cytometry cell sorting.通过流式细胞术细胞分选对罕见的慢性淋巴细胞白血病与淋巴浆细胞淋巴瘤复合病例进行MYD88突变分析。
Ann Hematol. 2015 Nov;94(11):1941-4. doi: 10.1007/s00277-015-2460-6. Epub 2015 Aug 2.
10
Clinicopathological characterization of chronic lymphocytic leukemia with MYD88 mutations: L265P and non-L265P mutations are associated with different features.MYD88 突变慢性淋巴细胞白血病的临床病理特征：L265P 和非 L265P 突变与不同特征相关。
Blood Cancer J. 2020 Aug 26;10(8):86. doi: 10.1038/s41408-020-00351-w.

引用本文的文献

1
Comparative analysis of patients' characteristics, treatment, and survival outcomes in CLL from China and the United States.中国和美国慢性淋巴细胞白血病患者特征、治疗及生存结局的比较分析。
Oncologist. 2025 Jul 4;30(7). doi: 10.1093/oncolo/oyaf181.
2
[The guidelines for diagnosis and treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma in China (2025)].《中国慢性淋巴细胞白血病/小淋巴细胞淋巴瘤诊断与治疗指南（2025年版）》
Zhonghua Xue Ye Xue Za Zhi. 2025 Feb 14;46(2):105-112. doi: 10.3760/cma.j.cn121090-20241209-00551.
3
A 47-Year-old Asian female with tracheobronchial space-occupying lesions caused by chronic lymphocytic leukemia.
一位 47 岁的亚裔女性，患有慢性淋巴细胞白血病导致的气管支气管腔占位性病变。
BMC Pulm Med. 2024 Oct 14;24(1):514. doi: 10.1186/s12890-024-03330-0.
4
Next-Generation Integrated Sequencing Identifies Poor Prognostic Factors in Patients with MYD88-Mutated Chronic Lymphocytic Leukemia in Taiwan.新一代整合测序鉴定台湾地区MYD88突变型慢性淋巴细胞白血病患者的不良预后因素
Pathobiology. 2025;92(2):77-89. doi: 10.1159/000541709. Epub 2024 Oct 2.
5
Improved efficacy and safety of zanubrutinib versus ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia (R/R CLL) in China: a subgroup of ALPINE.在复发/难治性慢性淋巴细胞白血病（R/R CLL）患者中，与伊布替尼相比，zanubrutinib 的疗效和安全性得到改善：ALPINE 的一个亚组。
Ann Hematol. 2024 Oct;103(10):4183-4191. doi: 10.1007/s00277-024-05823-8. Epub 2024 Jun 18.
6
Characteristics of chronic lymphocytic leukemia in Japan: Comprehensive analysis of the CLLRSG-01 study.日本慢性淋巴细胞白血病的特征：CLLRSG-01 研究的综合分析。
Int J Hematol. 2024 Jun;119(6):686-696. doi: 10.1007/s12185-024-03741-z. Epub 2024 Mar 16.
7
m6A-Modified circTET2 Interacting with HNRNPC Regulates Fatty Acid Oxidation to Promote the Proliferation of Chronic Lymphocytic Leukemia.m6A 修饰的 circTET2 与 HNRNPC 相互作用调节脂肪酸氧化以促进慢性淋巴细胞白血病的增殖。
Adv Sci (Weinh). 2023 Dec;10(34):e2304895. doi: 10.1002/advs.202304895. Epub 2023 Oct 11.
8
Machine learning models-based on integration of next-generation sequencing testing and tumor cell sizes improve subtype classification of mature B-cell neoplasms.基于下一代测序检测与肿瘤细胞大小整合的机器学习模型改善了成熟B细胞肿瘤的亚型分类。
Front Oncol. 2023 Aug 3;13:1160383. doi: 10.3389/fonc.2023.1160383. eCollection 2023.
9
[Current status of diagnosis and treatment of chronic lymphocytic leukemia in China: A national multicenter survey research].中国慢性淋巴细胞白血病的诊断与治疗现状：一项全国多中心调查研究
Zhonghua Xue Ye Xue Za Zhi. 2023 May 14;44(5):380-387. doi: 10.3760/cma.j.issn.0253-2727.2023.05.005.
10
Real-world treatment patterns, discontinuation and clinical outcomes in patients with B-cell lymphoproliferative diseases treated with BTK inhibitors in China.中国接受 BTK 抑制剂治疗的 B 细胞淋巴增生性疾病患者的真实世界治疗模式、停药和临床结局。
Front Immunol. 2023 Jul 7;14:1184395. doi: 10.3389/fimmu.2023.1184395. eCollection 2023.